reports
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc. CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx’s tender offer to acquire all of the issued and outstanding shares of common stock (the “Shares”) of Societal CDMO, at a purchase price of $1.1...
Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreR...
Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc. Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufa...
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Prom...
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. and ROUND ROCK, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: ), a contract development and manufacturing organization (CDMO) de...
Societal CDMO Reports Inducement Grants for New Staff
Societal CDMO Reports Inducement Grants for New Staff SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Societal CDMO’s board of directors approve...
Societal CDMO Reports Third Quarter 2023 Financial Results
Societal CDMO Reports Third Quarter 2023 Financial Results Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approximately $5.5 Million Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solvin...
Societal CDMO to Report Financial Results for Third Quarter 2023 on No...
Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023 Webcast Scheduled for Wednesday, November 8, 2023, at 4:30 p.m. Eastern SAN DIEGO and GAINESVILLE, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2023 after the market close on Wednesda...
Societal CDMO Reports Inducement Grants for New Staff
Societal CDMO Reports Inducement Grants for New Staff SAN DIEGO and GAINESVILLE, Ga., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Societal CDMO’s board of directors approve...
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Confe...
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will participate at the RBC Capital Markets Virtual CDMO Conference. David Enloe, chief executive officer, will be the featured speaker in a fireside chat at the conference...
Societal CDMO Announces Corporate Restructuring
Societal CDMO Announces Corporate Restructuring Strategic Realignment Designed to Right Size Organization to Address Macro Pharma Market Financing Challenges and Increase Operational Efficiency in Areas of Historical Strength SAN DIEGO and GAINESVILLE, Ga., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced a strategic restructuring plan to streamline and op...
Societal CDMO Secures Project Expansion Agreements With Several Existi...
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers Additional Work Across Facilities in California and Georgia to Include Analytical Method Development and Validation, Dissolution Testing, and Manufacturing of Prototype, Surrogate, and Engineering Batches SAN DIEGO and GAINESVILLE, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today a...
Societal CDMO Announces Closing of $8.3 Million Public Offering of Com...
Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company closed its previously announced underwritten public offering of 20,750,000 shares of its common stock (or common stock equivalents) at a public offering price of $0.40 per share of c...
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Com...
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock (or common stock equivalents) at a public offering price of $0.40 per share of common sto...
Societal CDMO Announces Appointment of Matt Arens to Board of Director...
Societal CDMO Announces Appointment of Matt Arens to Board of Directors Experienced Health Care Industry Investor with Track Record of Identifying Innovative Life Science Companies with High Growth Potential SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Matt Arens to the company’s board of directors. Mr. A...
Societal CDMO Announces Proposed Public Offering of Common Stock
Societal CDMO Announces Proposed Public Offering of Common Stock SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the shares of common stock (or common stock equivalents) are being offered by Societal. The ...
Societal CDMO Reports Second Quarter 2023 Financial Results
Societal CDMO Reports Second Quarter 2023 Financial Results Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency; Allows Expansion into Manufacture of Psychedelic Drug Products Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and m...
Societal CDMO to Report Financial Results for Second Quarter 2023 on A...
Societal CDMO to Report Financial Results for Second Quarter 2023 on August 9, 2023 Webcast Scheduled for Wednesday, August 9, 2023, at 4:30 p.m. Eastern SAN DIEGO and GAINESVILLE, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the second quarter 2023 after the market close on Wednesday,...
Societal CDMO Announces Expansion of Controlled Substance Manufacturin...
Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25 Years of Manufacturing of Schedule 2 Products No Additional Investment Required to Support Clinical Trials for Psychedelic-Based Therapeutics SAN DIEGO and GAINESVILLE, Ga., July 26, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; Nasdaq: ), a contract development and manufacturing organization (CDMO) dedicated to s...
Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Servic...
Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate Activities will be Conducted at Societal CDMO’s San Diego Facility and Span Analytic Method Transfer, Process Development, and CGMP Manufacturing SAN DIEGO and GAINESVILLE, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; Nasdaq: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announ...
Societal CDMO Reports Inducement Grants for New Staff
Societal CDMO Reports Inducement Grants for New Staff SAN DIEGO and GAINESVILLE, Ga., July 07, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Societal CDMO’s board of directors approved ...
Societal CDMO Signs Master Service Agreement With CivicaScript to Prov...
Societal CDMO Signs Master Service Agreement With CivicaScript to Provide CDMO Services Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process Development, and Clinical Trial Material Batch Manufacturing SAN DIEGO and GAINESVILLE, Ga., June 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the signing of a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.